Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study
Interim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a...
Coronavirus
Tonix Pharmaceuticals Completes Clinical Phase of PREVAIL Proof-of-Concept Study of TNX-102 SL for the Treatment of Fibromyalgia-Type Long COVID
Topline Results Expected Third Quarter 2023 Long COVID Afflicts Approximately 19% of Patients Following COVID-191, and is Expected to be...
XORTX Appoints Chief Financial Officer
CALGARY, Alberta, Aug. 04, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX...
Virogentics, Inc. Provides Update on African Project, European Medicine Agency Application and Clinical Trials for Application for Type 2 Diabetes
Progress on Sagaliam Acquisition Corp TransactionALLEN, TX / ACCESSWIRE / August 4, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).Virogentics, Inc....
Recce Pharmaceuticals Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives
SYDNEY, Australia, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new...
Precipio’s Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven
These efficiencies plus revenue growth expected to continue the positive momentumNEW HAVEN, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Specialty...
Aridis Pharmaceuticals Announces $2 Million Offering
Los Gatos, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS), a biopharmaceutical company focused on the...
DLH to Expand Digital Transformation Services at the National Heart, Lung, and Blood Institute
ATLANTA, Aug. 02, 2023 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of...
Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering
SEATTLE, WA / ACCESSWIRE / August 1, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical stage...
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
Phase 2 study initiated at clinical sites in Australia with monovalent and bivalent mRNA COVID-19 vaccine candidatesVaccine candidates developed in...
Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023
Revenue growth and customer pipeline advance the Company towards breakevenNEW HAVEN, Conn., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Specialty cancer...
Sorrento Issues a “FAQ” in Response to Large Number Of Urgent Requests from Scilex Dividend Short Holders and/or Record Holders
SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the...
Vaxart to Host Second Quarter 2023 Business Update and Financial Results Conference Call on August 3
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc....
Sernova Expands Leadership Team with Appointment of Modestus Obochi, Ph.D., MBA, as Chief Business Officer
LONDON, Ontario, July 26, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-stage company and...
Predictmedix AI Engages in Partnership with Indian Supplier for Mass Production and Rapid Deployment of Safe Entry Stations
TORONTO, ON / ACCESSWIRE / July 25, 2023 / Predictmedix AI Inc. (CSE:PMED)(OTCQB:PMEDF)(FRA:3QP) (the "Company" or "Predictmedix") is pleased to...
Emergex Reports Promising Data from Completed Swiss Phase I Trial of CoronaTcP™, T Cell-Priming Immune Set-Point Candidate for Betacoronaviruses
First-in-human intradermal administration of CoronaTcP™ was generally well-toleratedEvidence for generation of virus-specific effector and memory CD8+ T cellsData reinforce findings...
Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML
Phase 2 Trials in Relapsed/Refractory and Frontline Settings Planned, APVO436 to be administered in Combination with Emerging Standard of CareNew...
Intellipharmaceutics Announces Second Quarter 2023 Results
TORONTO, ON / ACCESSWIRE / July 14, 2023 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a...
Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down
In line with the Company’s Fix, Fund, Propel approach, Dana J Moss, JD joins Navidea’s Board, adding depth in legal...
Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation
QIDP designation for Biologics provides FDA Priority Review statusLOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc....